A Pilot, Multicenter, Single Arm, Open Label, Surgical Window of Opportunity Study of Abemaciclib and Letrozole for Endometrioid Adenocarcinoma of the Endometrium

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 12 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

04 Jun 2024 Results hypothesizing that the combination of letrozole and abemaciclib will inhibit cellular proliferation, as measured by Ki-67, in patients with endometrial cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
30 Apr 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2022.
12 Aug 2019 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com